stockrowWhat it does
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company that discovers, develops and sells treatments for neurological, psychiatric, endocrine and immunological disorders. Founded in 1992, it is headquartered in San Diego.
Its largest product, INGREZZA, treats tardive dyskinesia, a condition involving involuntary movements, and chorea associated with Huntington’s disease. CRENESSITY treats classic congenital adrenal hyperplasia, or CAH, a genetic disorder that affects hormone production. Neurocrine sells both medicines in the United States.
The company also sells VYKAT XR, which it acquired in May 2026. VYKAT XR treats hyperphagia, or excessive hunger, in people with Prader-Willi syndrome. Neurocrine uses a specialized pharmacy to supply the medicine and provides support to patients and prescribers.
Neurocrine also has approved treatments for endometriosis and uterine fibroids through a collaboration with AbbVie. AbbVie holds global commercialization rights to elagolix, the medicine used for those conditions. In Japan and select other Asian markets, Tanabe Pharma holds commercialization rights to valbenazine, the active ingredient in INGREZZA.
Beyond its marketed medicines, Neurocrine develops candidates for conditions including depression, schizophrenia, epilepsy and obesity. These candidates must complete development and receive regulatory approval before they can be sold. Its pipeline includes conventional small-molecule drugs as well as peptides, proteins, antibodies and gene therapies.
How it makes money
Neurocrine earns most of its revenue by selling medicines. It also earns collaboration revenue, primarily royalties on AbbVie’s net sales of elagolix and Tanabe Pharma’s net sales of valbenazine. The company reports its business as one reportable segment.
In FY2025, net product sales were $2.8 billion; in the third quarter of 2026, they were more than $1.1 billion.
INGREZZA generated $2.51 billion of net product sales in 2025. CRENESSITY generated $301.2 million in its first full year of launch. Total product sales increased as both medicines grew, although INGREZZA’s net price fell because of investments in market access. Product sales represented 99.1% of revenue in FY2025, with collaboration revenue accounting for most of the remainder.
In the third quarter of 2026, INGREZZA sales were $801 million, CRENESSITY sales were $211 million and VYKAT XR sales were $107 million. INGREZZA’s quarterly sales included a $20 million benefit from customer order timing that Neurocrine expected to reverse in the fourth quarter.
Revenue from the medicines depends on prescriptions and patients continuing treatment, as well as the net price after discounts and allowances. Neurocrine said CRENESSITY’s third-quarter performance was supported by patient additions, persistence and reimbursement. For VYKAT XR, it said quarterly growth reflected new patient demand rather than pricing. The company expects INGREZZA volume growth in 2027 to more than offset net pricing headwinds.
| Product or service | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| Net product sales | $2.8 billion | 99.1% | 21.6% |
| Collaboration revenues | $26.6 million | 0.93% | 7.69% |
Customers and how it sells
Neurocrine sells INGREZZA exclusively in the United States through a limited specialty network. Its direct customers include select specialty pharmacy providers, wholesale distributors and specialty distributors. CRENESSITY is sold in the United States through a single specialty pharmacy provider. VYKAT XR is also supplied through a single specialized pharmacy, with support for patients and prescribers.
One customer accounted for 39.0% of FY2025 revenue. The company uses third-party logistics providers for packaging, warehousing and shipping its products.
Prescribers and patients are reached by a U.S. sales force focused on neurology, psychiatry, long-term care and rare diseases. Neurocrine also works with payers to secure coverage. It said its INGREZZA contracts executed in 2025 covered about 70% of Medicare lives in 2026.
Outside the United States, commercialization is handled through partners for certain medicines. Tanabe Pharma holds rights to valbenazine in Japan and select Asian markets, while AbbVie holds global commercialization rights to elagolix. Neurocrine receives royalties on their sales.
| Segment | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| Reportable Segment | $2.9 billion | 100.0% | 21.4% |
Suppliers and costs
Neurocrine relies on third-party manufacturers to produce INGREZZA, CRENESSITY and its product candidates. Raw materials, active pharmaceutical ingredients and other supplies come from third-party manufacturers and suppliers. The company has long-term supply and manufacturing agreements with multiple manufacturers and intends to continue using outsourced production.
Those manufacturers and suppliers must comply with manufacturing standards and can be inspected by regulators. Neurocrine depends on its partners and its own quality oversight to maintain compliance. It also outsources packaging, warehousing and shipment.
Costs include manufacturing and royalties, research and development, employee compensation, facilities and commercial operations. In 2025, late-stage development spending increased with investment in the osavampator and direclidine programs. Selling, general and administrative spending also rose as Neurocrine invested in its commercial organization.
Some CRENESSITY inventory sold in 2025 had been charged to research and development before approval, reducing that year’s cost of revenue. Neurocrine expects future cost of revenue to include active ingredient produced after approval.
- Revenue$2.9B
- Cost of revenue−$52.1M
- Research and development−$1.0B
- Selling, general and administrative−$1.2B
- Other operating costs−$17.4M
- Operating income$619.1M
Competitive position
INGREZZA competes with AUSTEDO, marketed by Teva Pharmaceuticals Industries, for tardive dyskinesia and chorea associated with Huntington’s disease. Other medicines are also used off-label for tardive dyskinesia, including XENAZINE and its generic equivalents. CRENESSITY competes with high-dose corticosteroid treatment, the current standard of care for CAH, as well as potential treatments in development.
For schizophrenia, Neurocrine’s investigational direclidine could compete with existing medicines, including COBENFY, and development-stage programs. Neurocrine is also watching AbbVie’s emraclidine program. Its depression and other pipeline candidates may face both marketed medicines and treatments under development.
INGREZZA is covered by 22 issued U.S. patents listed in the FDA Orange Book, with expirations between 2027 and 2040. Settlement agreements permit the companies involved to sell generic INGREZZA in the United States beginning March 1, 2038, or earlier under certain circumstances. CRENESSITY has four listed U.S. patents expiring between 2035 and 2041 and seven years of orphan drug exclusivity.
Our reading: Patents and exclusivity provide meaningful protection, but the INGREZZA settlements set a route for generic entry and existing branded treatments already compete. Our reading: Neurocrine’s specialized distribution and sales teams support access to prescribers and patients, but they do not prevent competing medicines from reaching those markets.
| Competitor | Where they compete | Threat (our reading) |
|---|---|---|
| Teva Pharmaceuticals Industries | Tardive dyskinesia and Huntington’s disease chorea | High |
| AbbVie | Investigational treatments for schizophrenia | Medium |
Growth opportunities
Neurocrine’s commercial strategy includes reaching more patients and prescribers with INGREZZA and CRENESSITY. The company estimates that tardive dyskinesia affects approximately 800,000 people in the United States and that CAH affects at least 20,000. It said more than 15% of the estimated diagnosed classic CAH population had been prescribed CRENESSITY by the third quarter of 2026.
VYKAT XR adds another commercial medicine. Neurocrine plans to study its use in people with Prader-Willi syndrome and complex health issues in 2027. The company also said recent external events could delay the growth trajectory it expected for the product.
The development pipeline offers other potential routes to growth. Neurocrine expects Phase 3 data readouts in 2027 for osavampator in major depressive disorder and direclidine in schizophrenia. It has also initiated a Phase 2 study of NBI-1117567 as an adjunctive treatment for cognition in Alzheimer’s disease.
In obesity, Neurocrine has started Phase 1 development of NBIP-’1968 and is also studying NBIP-’2118. It is developing a gene therapy for Friedreich’s ataxia with Voyager Therapeutics and expects it to enter Phase 1, with initial patient-level data anticipated in 2027. These investigational programs require further testing and regulatory approval before commercialization.
- $1.1BFY2021
- $1.5BFY2022
- $1.9BFY2023
- $2.4BFY2024
- $2.9BFY2025
Structural risks
- Commercialization and reimbursement: Acceptance of INGREZZA and CRENESSITY can be affected by pricing, cost-effectiveness, safety, payer coverage and adequate reimbursement. Existing or new competing products can also affect demand.
- Clinical development: Candidates may prove ineffective, cause harmful side effects, fail to replicate earlier results or fail to obtain regulatory approval. Trials can also be delayed or suspended.
- Manufacturing and distribution: Neurocrine relies on third parties to manufacture, package, warehouse and ship products. Its manufacturers and suppliers are subject to regulatory quality requirements.
- Intellectual property and generics: INGREZZA patent settlements permit generic sales beginning March 1, 2038, or earlier under certain circumstances. Other drug technologies and generic equivalents may make products or candidates less competitive.
- Government investigation: In August 2025, the U.S. Department of Justice requested documents and information relating to INGREZZA sales and marketing. Neurocrine is cooperating and cannot assure the timing or outcome.
- Product safety and use: VYKAT XR’s label provides guidance on side effects associated with diazoxide, including hyperglycemia and fluid. Neurocrine has emphasized patient selection, dose titration and monitoring for adverse events.
Bottom line
Our reading
Neurocrine is a medicine-selling business whose 2025 sales depended heavily on INGREZZA, even as CRENESSITY and the acquired VYKAT XR broaden its commercial portfolio. Its opportunity to expand rests on reaching more patients and advancing its pipeline; its exposure includes reimbursement, competition, clinical outcomes and eventual generic entry. Outsourced manufacturing and specialized distribution are central to how it delivers those medicines.